A carregar...
Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use
Alemtuzumab is a humanized monoclonal antibody therapy that has recently been approved in over 30 countries for patients with active relapsing-remitting multiple sclerosis. It acts by targeting CD52, an antigen primarily expressed on T and B lymphocytes, resulting in their depletion and subsequent r...
Na minha lista:
| Publicado no: | Ther Adv Neurol Disord |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4286943/ https://ncbi.nlm.nih.gov/pubmed/25584072 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1756285614563522 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|